Brivaracetam CAS 357336-20-0

Product Description:

Product Name: Brivaracetam CAS 357336-20-0

Synonyms:

(alphaS,4R)-alpha-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide;

(S)-2-((R)-2-oxo-4-propylpyrrolidin-1-yl)butanamide;

2(S)-[2-Oxo-4(R)-propylpyrrolidin-1-yl]butyramide;

Chemical & Physical Properties

Appearance: White to Off-White powder

Assay: NLT99%

Melting Point: 72-78℃

Density: 1.1±0.1 g/cm3

Boiling Point:409.3±28.0 ℃ at 760 mmHg

Flash Point: 201.3±24.0℃

Solubility: DMSO (Slightly), Methanol (Slightly)

Application: Brivaracetam is a new generation of antiepileptic drugs approved by the FDA for the treatment of localized seizures in epilepsy patients aged 16 and above. It can be used in laboratory research and pharmaceutical development processes.

Brivaracetam is approved by the US Food and Drug Administration (FDA) for the adjuvant treatment of partial seizures in patients aged 16 and above. Compared with the previous generation drug levetiracetam, brivaracetam has a similar chemical structure and mechanism of action, making it the first anti epileptic drug approved by the FDA to treat partial seizures since 2013.

Brivaracetam is a highly selective and affinity synaptic vesicle protein 2A ligand approved for the treatment of partial seizures in adults and adolescents aged 16 and above, with or without secondary systemic seizures as an adjuvant therapy.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.